DrugPatentWatch Database Preview

Details for Patent: 10,016,396

« Back to Dashboard

Which drugs does patent 10,016,396 protect, and when does it expire?

Patent 10,016,396 protects PRECEDEX and is included in one NDA.

This patent has forty patent family members in twenty-seven countries.

Summary for Patent: 10,016,396

Title:	Dexmedetomidine premix formulation
Abstract:	The presently disclosed subject matter relates to pharmaceutical compositions comprising dexmedetomidine or a pharmaceutically acceptable salt thereof wherein the composition is formulated as a liquid for parenteral administration to a subject, and wherein the composition is disposed within a sealed container as a premixture. The pharmaceutical compositions can be used, for example, in perioperative care of a patient or for sedation.
Inventor(s):	Roychowdhury; Priyanka (Foster City, CA), Cedergren; Robert A. (Libertyville, IL)
Assignee:	HOSPIRA, INC. (Lake Forest, IL)
Application Number:	15/444,932
Patent Claim Types: see list of patent claims

Drugs Protected by US Patent 10,016,396

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Hospira	PRECEDEX	dexmedetomidine hydrochloride	INJECTABLE;INJECTION	021038-002	Mar 13, 2013	AP	RX	Yes	Yes			Y
Hospira	PRECEDEX	dexmedetomidine hydrochloride	INJECTABLE;INJECTION	021038-003	Mar 13, 2013	AP	RX	Yes	Yes			Y

International Family Members for US Patent 10,016,396

Country	Document Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	089673
Australia	2013201069
Brazil	112013008005
Canada	2806706
Chile	2013000815
China	103281902